Using Adapted Argentine Tango to Help Breast Cancer Survivors with Neuropathy
DANCE-BASED AVENUES TO ADVANCE NONPHARMACOLOGIC TREATMENT OF CHEMOTHERAPY EFFECTS (DAANCE): A MULTICENTER TRIAL
This study is testing whether adapted Argentine Tango can help breast cancer survivors with nerve pain from chemotherapy feel better and improve their movement.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 140 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Ohio State University Comprehensive Cancer Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (New Haven, Connecticut and 1 other locations) |
| Trial ID | NCT06749210 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of a noninvasive, social sensorimotor intervention, specifically Adapted Argentine Tango, on breast cancer survivors suffering from chemotherapy-induced neuropathy. The study aims to restore motor control, alleviate symptoms, and enhance patient participation in treatment through partnered dance. It builds on previous pilot work and will involve a diverse cohort of participants to assess the intervention's effectiveness in improving sensory relief and functional restoration.
Who should consider this trial
Good fit: Ideal candidates include breast cancer survivors who have completed taxane-based chemotherapy at least three months prior and are experiencing symptoms of chemotherapy-induced neuropathy.
Not a fit: Patients with pre-existing vestibular dysfunction, poorly controlled diabetes, or those currently undergoing activity-based therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the quality of life for breast cancer survivors by alleviating neuropathy symptoms and reducing fall risk.
How similar studies have performed: Other studies have shown promising results with similar noninvasive interventions, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Breast Cancer (BC) diagnosis of Stage I-IV including metastatic disease * completed taxane-based chemotherapy for BC at least 3 months ago (no limit on how long ago) * symptomatic for chemotherapy-induced neuropathy (self-report) * postural control score that indicates potential fall-risk * able to understand and comply with directions associated with testing and study treatments Exclusion Criteria: * pre-existing vestibular dysfunction * poorly controlled diabetes (hgA1C\>=8) * non-ambulatory (assistive and prosthetic devices allowed) * hearing impairment resulting in less than 10% hearing bilaterally * contraindication to participate in the experimental physical activity per the treating oncologist due to additional condition (e.g., herniated disc, unstable bone metastases) * currently in activity-based therapy (e.g., physical therapy, occupational therapy). May enroll if still meet eligibility criteria once activity-based therapy is complete.
Where this trial is running
New Haven, Connecticut and 1 other locations
- Yale University — New Haven, Connecticut, United States (Recruiting)
- The Ohio State University — Columbus, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Lise B Worthen-Chaudhari, PhD, MFA, CMES — Ohio State University
- Study coordinator: Lise Worthen-Chaudhari, PhD, MFA, CMES
- Email: lise.worthen-chaudhari@osumc.edu
- Phone: (1) + 614-293-6281
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.